The market for dry eye disease treatments is fueled by various factors, such as an aging population more susceptible to the condition and the growing use of digital devices, which contribute to eye strain and dryness. Additionally, heightened awareness of dry eye disease, along with its increasing prevalence linked to chronic illnesses like diabetes and autoimmune disorders, has amplified the demand for effective treatment options. LAS VEGAS , Oct.
31, 2024 /PRNewswire/ -- DelveInsight's Dry Eye Disease Treatment Market Insights report provides the current and forecast market analysis, individual leading dry eye disease treatment companies' market shares, challenges, dry eye disease treatment market drivers, barriers, trends, and key market dry eye disease treatment companies in the market. Key Takeaways from the Dry Eye Disease Treatment Market Report As per DelveInsight estimates, North America is anticipated to dominate the global dry eye disease treatment market during the forecast period. In the product type segment of the dry eye disease treatment market, the artificial tear category captured a significant revenue share in 2023.
Notable dry eye disease treatment companies such as Alcon Inc., AbbVie Inc., Johnson & Johnson Vision Care, Inc.
, Horus Pharma, Sun Pharmaceutical Industries Ltd., OASIS Medical, Inc., VISUfarma, Sentiss Pharma Pvt.
Ltd., Santen Pharmaceutical Co. Ltd.
, Otsuka Pharmaceutical Co., Ltd., Novaliq GmbH, AFT Pharmaceuticals.
, Novartis AG, Sight Scien.
